Author

Radboud J Duintjer Tebbens

Kid Risk, Inc. - Cited by 3,497 - Polio eradication - dynamic modeling - risk analysis - health economics - uncertainty analysis

Biography

Radboud J Duintjer Tebbens use modeling and analytics in innovative ways to help organizations achieve better outcomes. A recognized expert with over 15 years of experience in integrating different analytical tools to model high-impact decisions, his work influenced and helped fund the world's largest global disease eradication initiative. More recently, he defined statistical safety validation strategies for autonomous vehicles and am integrating novel methods to define and assess driving behavior into the system engineering process for autonomous vehicles.
Title
Cited by
Year
Expert review on poliovirus immunity and transmission
RJ Duintjer Tebbens, MA Pallansch, KM Chumakov, NA Halsey, T Hovi, ...Risk Analysis 33 (4), 544-605, 2013201
112
2013
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine‐derived polioviruses (cVDPVs)
RJ Duintjer Tebbens, MA Pallansch, JH Kim, CC Burns, OM Kew, ...Risk analysis 33 (4), 680-702, 2013201
102
2013
Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine‐related polioviruses
RJ Duintjer Tebbens, MA Pallansch, DA Kalkowska, SGF Wassilak, ...Risk Analysis 33 (4), 703-749, 2013201
97
2013
Modeling the dynamics of oral poliovirus vaccine cessation
KM Thompson, RJ Duintjer TebbensThe Journal of infectious diseases 210 (suppl_1), S475-S484, 2014201
91
2014
Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs
RJ Duintjer Tebbens, MA Pallansch, KM Chumakov, NA Halsey, T Hovi, ...Risk Analysis 33 (4), 606-646, 2013201
83
2013
Modeling population immunity to support efforts to end the transmission of live polioviruses
KM Thompson, MA Pallansch, RJD Tebbens, SG Wassilak, SL CochiRisk Analysis, 2012201
78
2012
An economic analysis of poliovirus risk management policy options for 2013–2052
RJ Duintjer Tebbens, MA Pallansch, SL Cochi, SGF Wassilak, ...BMC Infectious Diseases 15, 1-21, 2015201
72
2015
Modeling options to manage type 1 wild poliovirus imported into Israel in 2013
DA Kalkowska, RJ Duintjer Tebbens, I Grotto, LM Shulman, E Anis, ...The Journal of infectious diseases 211 (11), 1800-1812, 2015201
65
2015
Preeradication vaccine policy options for poliovirus infection and disease control
KM Thompson, MA Pallansch, RJ Duintjer Tebbens, SG Wassilak, JH Kim, ...Risk Analysis 33 (4), 516-543, 2013201
62
2013
Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar
C Schaetti, MG Weiss, SM Ali, CL Chaignat, AM Khatib, R Reyburn, ...Public Library of Science 6 (10), e1844, 2012201
61
2012
Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination
DA Kalkowska, RJ Duintjer Tebbens, MA Pallansch, SL Cochi, ...BMC infectious diseases 15, 1-12, 2015201
57
2015
The potential impact of expanding target age groups for polio immunization campaigns
RJ Duintjer Tebbens, DA Kalkowska, SGF Wassilak, MA Pallansch, ...BMC Infectious Diseases 14 (1), 1-17, 2014201
55
2014
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation
RJ Duintjer Tebbens, KM ThompsonThe Journal of Infectious Diseases 210 (suppl_1), S485-S497, 2014201
53
2014
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
RJ Duintjer Tebbens, LM Hampton, KM ThompsonBMC infectious diseases 16 (1), 1-16, 201652201
52
2016
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
RJ Duintjer Tebbens, MA Pallansch, SGF Wassilak, SL Cochi, ...BMC Infectious Diseases 16 (1), 1-19, 2016201
51
2016
Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria
DA Kalkowska, RJ Duintjer Tebbens, KM ThompsonThe Journal of Infectious Diseases 210 (suppl_1), S412-S423, 201449201
49
2014
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
RJ Duintjer Tebbens, MA Pallansch, KM ThompsonBMC infectious diseases 15 (1), 1-18, 2015201
48
2015
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication
KM Thompson, RJ Duintjer TebbensExpert review of vaccines 13 (2), 221-234, 2014201
45
2014
Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses
KM Thompson, DA Kalkowska, RJD TebbensVaccine 33 (13), 1568-1577, 2015201
39
2015
Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems
RJ Duintjer Tebbens, M Zimmermann, MA Pallansch, KM ThompsonFood and environmental virology 9 (4), 361-382, 2017201
39
2017

Referred From: https://scholar.google.com/citations?hl=en&user=jgeWbOMAAAAJ

Cited by
Citations 3497
h-index 38
i10-index 69
Recommended Journals
Open Access Journals